It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
By its own reckoning, the UK’s tough watch dog on drug pricing has said that these drugs would be worth up to $649,000 a year, given the young patients it’s targeting first. Analysts, meanwhile, have pegged the price at anywhere from $400,000 to $750,000.
Novartis (NVS -1%) has assuaged investors in Gilead Sciences (GILD +5.2%) that CAR-T pricing may be an issue. It announced that its just-approved Kymriah (tisagenlecleucel) will cost $475K per treatment, toward the low end of analysts' projected range of $400K - 750K.
Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.
If CMS agrees and implements the scheme, then the price should be substantially higher than $475K considering the "life value" of young patients who respond.
It also said that it is working with CMS on an outcomes-based approach to reimbursement that will allow payment for only those ALL patients that respond to treatment by the end of one month.
originally posted by: Mandroid7
So someone should learn the process and synthesize it. Cut them all out of the loop.